Cargando…
Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists
CLEC-2 is a target for a new class of antiplatelet agent. Clustering of CLEC-2 leads to phosphorylation of a cytosolic YxxL and binding of the tandem SH2 domains in Syk, crosslinking two receptors. We have raised 48 nanobodies to CLEC-2 and crosslinked the most potent of these to generate divalent a...
Autores principales: | Clark, Joanne C., Martin, Eleyna M., Morán, Luis A., Di, Ying, Wang, Xueqing, Zuidscherwoude, Malou, Brown, Helena C., Kavanagh, Deirdre M., Hummert, Johan, Eble, Johannes A., Nieswandt, Bernhard, Stegner, David, Pollitt, Alice Y., Herten, Dirk-Peter, Tomlinson, Michael G., García, Angel, Watson, Steve P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082178/ https://www.ncbi.nlm.nih.gov/pubmed/37029319 http://dx.doi.org/10.1038/s42003-023-04766-6 |
Ejemplares similares
-
Katacine Is a New Ligand of CLEC-2 that Acts as a Platelet Agonist
por: Morán, Luis A., et al.
Publicado: (2022) -
CLEC-2 Prevents Accumulation and Retention of Inflammatory Macrophages During Murine Peritonitis
por: Bourne, Joshua H., et al.
Publicado: (2021) -
Antibody-mediated depletion of human CLEC-2 in a novel humanized mouse model
por: Brown, Helena C., et al.
Publicado: (2022) -
CLEC‐2‐dependent activation of mouse platelets is weakly inhibited by cAMP but not by cGMP
por: Borgognone, A., et al.
Publicado: (2014) -
G6b-B Inhibits Constitutive and Agonist-induced Signaling by Glycoprotein
VI and
CLEC-2
por: Mori, Jun, et al.
Publicado: (2008)